Table 4

Univariate logistic regression for patients undergoing bilateral salpingo-oophorectomy (n=234) versus ovarian suppression (n=282) for ovarian ablation

LevelsOR95% CI lower bounds95% CI upper boundsp value
Age at diagnosisAs one year increase1.0511.0211.082 <0.001
Year of diagnosis2011 vs 20101.0750.5891.9600.082
2012 vs 20100.8320.4591.508
2013 vs 20100.5810.3291.025
2014 vs 20100.5970.3481.023
Family history (15 unknown)Yes vs no1.0340.7241.4770.852
Live childrenYes vs no1.3620.9102.0380.133
HistologyLobular no ductal vs ductal no lobular0.9270.5341.6090.176
Lobular and ductal vs ductal no lobular2.5221.1925.334
Inflammatory vs ductal no lobular0.6300.0577.007
Other vs ductal no lobular0.8410.1395.083
Grade (32 unknown)G2 vs G10.6390.2101.9410.286
G3 vs G10.8920.3072.598
LN pos exact (2 unknown)Yes vs No0.9010.6361.2750.556
Stage (59 unknown)II vs I1.1300.7451.7130.777
III vs I0.9620.5901.568
ChemotherapyYes vs no1.1790.8061.7270.396
HER-2 targetedTrastuzumab vs none1.5870.9022.7900.076
Trastuzumab+other vs none1.8510.9293.691
  • The OR is modeled for BSO yes, as OR>1 means more likely to get BSO, OR<1 less likely to get BSO. Unknown=number of patients in analysis who did not have documentation for this variable.

  • Bold p values represent p values of significance.

  • BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; LN, lymph node; OS, ovarian suppression.